Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Small Study Of Novartis Asthma Drug Shows Promising Results

XTALKS VITALS NEWS

Asthma

The oral drug is a departure from traditional asthma inhalers, in which the medication is delivered directly into the lungs.

Tweetables from this article:

Tweet: #Asthma drug could lower inflammatory #biomarkers more effectively when compared to the placebo http://ctt.ec/c_o6b+Asthma drug could lower inflammatory biomarkers more effectively when compared to the placebo.

Tweet: By the year 2020, the US market for #asthma drugs is expected to reach $14 billion http://ctt.ec/P0dpl+By the year 2020, the US market for asthma drugs is expected to reach $14 billion.

Share this!

August 9, 2016 | by Sarah Massey, M.Sc.

An experimental asthma medication developed by Novartis has shown promising results in a recent small investigational study. The results – which were published in the journal, The Lancet Respiratory Medicine – suggest that the drug could lower inflammatory biomarkers more effectively when compared to the placebo.

The trial involved 61 patients who were randomly assigned to receive the experimental drug, called fevipiprant, or a placebo. The drug is a prostaglandin D2 receptor 2 antagonist, and was successful at significantly reducing the eosinophil count in those with moderate to severe asthma.

The oral drug is a departure from traditional asthma inhalers, in which the medication is delivered directly into the lungs. According to Reuters, the Swiss drugmaker hopes to file for regulatory approval in 2019.



To meet that goal, Novartis will need to conduct further studies involving more patients in order to prove the efficacy of fevipiprant. If approved, the drug could be the first new oral treatment for asthma since the 1950s.

By the year 2020, the US market for asthma drugs is expected to reach $14 billion, according to GBI Research. In 2013, the market was worth $11.7 billion.

While pharma giants GlaxoSmithKline, Merck and AstraZeneca are all major players in the asthma space, Novartis is hoping to gain market share with fevipiprant. As much of the R&D into new asthma therapies has focused on inhaled drugs, most of the top-selling medications for the respiratory condition utilize that form of drug delivery.

The current study was conducted at Glenfield Hospital in Leicester, UK. Fevipiprant was described as having a good safety profile, with no serious adverse events reported.


Keywords: Asthma, Biomarker, Drug Delivery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News


New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.